Meet John Adlesich and some of his healthcare ideas

John Adlesich or the rise of a health industry executive professional on healthcare industry trends: COVID-19 has exposed vulnerability at health care organizations across the globe on critical issues, including safety, equipment, data availability, and infrastructure. Early on, it became apparent that “going it alone,” in terms of depending on an organization’s own supply lines and capabilities, wasn’t possible. This led to ad hoc collaborations, with providers, suppliers and non-health-care companies jumping in to deliver resources and capacity to address the crisis. Successful organizations will build upon this mindset, finding ways to close gaps and innovate with partners that bring unique skills to solve problems.

John Adlesich on behavior therapy in 2021: What Is Behavior Therapy? The basic premise of behavioral therapy stems from the Skinnerian theory of operant conditioning, which asserts that behavior is learned, and thus, can be unlearned or modified to comply with socially accepted norms. By evaluating and analyzing behaviors and subsequently offering a reward, also called a consequence, for those behaviors that are socially significant and desirable, maladaptive and/or undesirable behaviors can be reshaped or eliminated. Applied Behavioral Analysis is a highly effective method for mediating behavior across a variety of domains.

John Adlesich about healthcare industry trends: With President Joe Biden’s inauguration on January 20, the healthcare industry will be watching for the new administration’s priorities around the ACA and its COVID-19 plan, as well as who will be on the administration’s healthcare team and on which policies it focuses. While ACA repeal was a constant threat under the last administration, the Act looks more secure following recent developments. The ACA’s future likely hinges on the constitutionality of the individual mandate and potential severability under the California versus Texas case, which the U.S. Supreme Court is currently considering. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.

John Adlesich believes that 2021 is a defining year for the health industry. While a balanced approach is important, there is no question that US-based sources for many products are lacking to non-existent. To remedy this imbalance, we may see tax incentives and low-cost loans that would enable American manufacturers to invest in new automation technologies, to help level the playing field with overseas companies that have access to cheap labor and fewer regulatory barriers. There may also be new requirements that government purchasers such as the Veteran’s Administration and Department of Defense purchase at least a portion of the medical products they use from domestic suppliers. More, too, should be done to incent our health care providers to purchase domestically. Such moves would go a long way to creating the demand necessary for added domestic investments. When added incentives are required, the private sector will continue to step in to reward manufacturers that place a premium on geographic diversity for their supply chains. For instance, after learning that 90 percent of all face masks were produced in China, leaving the US highly susceptible to shortages, Premier and 16 leading health systems pooled resources to take a minority stake in Prestige Ameritech, one of the nation’s only domestic producers of face masks and other personal protective equipment. In exchange for the cash infusion and long-term purchasing commitments, the company is now making 3.5 million masks per month that it ordinarily would have had little incentive to make. In November, we followed that initiative with a partnership with 34 members to invest in DeRoyal Industries for the domestic production of isolation gowns that have increasingly been difficult to find.